Latest News and Press Releases

NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production

NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications

NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.

NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment

NurExone Biologic welcomes Prof. Teodoro Forcht Dagi, a renowned neurosurgeon and life science venture capitalist, to its Scientific Advisory Board.

NurExone has been awarded a grant by the Israel Innovation Authority (“IIA”) as part of the Israel-Canada bilateral Eureka program